The price of Akero Therapeutics Inc (NASDAQ: AKRO) closed at $49.24 in the last session, down -2.61% from day before closing price of $50.56. In other words, the price has decreased by -$2.61 from its previous closing price. On the day, 0.83 million shares were traded. AKRO stock price reached its highest trading level at $50.6899 during the session, while it also had its lowest trading level at $49.21.

Ratios:

We take a closer look at AKRO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 16.80 and its Current Ratio is at 16.80. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on January 30, 2025, Upgraded its rating to Buy and sets its target price to $63 from $35 previously.

On January 27, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $50 to $72.

On November 18, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $65.Citigroup initiated its Buy rating on November 18, 2024, with a $65 target price.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 16 ’25 when Yale Catriona sold 10,000 shares for $52.95 per share. The transaction valued at 529,467 led to the insider holds 91,488 shares of the business.

Cheng Andrew sold 30,000 shares of AKRO for $1,534,895 on Jul 10 ’25. The President and CEO now owns 520,757 shares after completing the transaction at $51.16 per share. On Jul 07 ’25, another insider, Rolph Timothy, who serves as the Chief Scientific Officer of the company, sold 12,500 shares for $51.09 each. As a result, the insider received 638,661 and left with 167,124 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 4030520576 and an Enterprise Value of 3275225088.

Stock Price History:

The Beta on a monthly basis for AKRO is -0.29, which has changed by 0.85043216 over the last 52 weeks, in comparison to a change of 0.17535925 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $21.34. The 50-Day Moving Average of the stock is -3.93%, while the 200-Day Moving Average is calculated to be 20.99%.

Shares Statistics:

According to the various share statistics, AKRO traded on average about 1.58M shares per day over the past 3-months and 899050 shares per day over the past 10 days. A total of 79.67M shares are outstanding, with a floating share count of 71.78M. Insiders hold about 9.95% of the company’s shares, while institutions hold 101.97% stake in the company. Shares short for AKRO as of 1752537600 were 8164232 with a Short Ratio of 5.18, compared to 1749772800 on 7751439. Therefore, it implies a Short% of Shares Outstanding of 8164232 and a Short% of Float of 10.5399996.

Earnings Estimates

The market rating for Akero Therapeutics Inc (AKRO) is a result of the insights provided by 5.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.96, with high estimates of -$0.91 and low estimates of -$1.01.

Analysts are recommending an EPS of between -$3.46 and -$3.94 for the fiscal current year, implying an average EPS of -$3.78. EPS for the following year is -$4.42, with 8.0 analysts recommending between -$4.02 and -$4.91.